NCT05567159View on ClinicalTrials.gov

A Study of Donanemab (LY3002813) in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

October 4, 2022

Primary Completion Date

July 14, 2023

Study Completion Date

July 14, 2023

Conditions

Healthy

Interventions

DRUG

Donanemab

Administered IV.

Trial Locations (1)

84124

ICON Early Phase Services Lenexa Center, Salt Lake City

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY